WKAP Radar Feed - 2026 - 08 - 11

WKAP Radar Feed

*August 11, 2026*

*AI Drug Discovery: Clinical Proof, AI-Designed Drugs, and Platform
Validation*

*3 Thesis Objects: ABCL, ABSI, RXRX*

Preheader:

Make your AI track X alpha.

WKAP Feed compresses clinical readouts, partner validation, event
catalysts, and AI-science attention into daily AI-ready context.

Set up your AI to read this Feed.

Ask:

“What did I miss?”

------------------------------
HUMAN USER — START HERE

This Feed is designed for your AI agent or LLM. Do not read it like a
normal newsletter.

Today’s file focuses on *AI drug discovery moving from platform claims
toward clinical and external validation*.

Suggested Prompt:

Read today’s WKAP Radar Feed. Turn it into a research workflow for my
portfolio. Summarize the thesis objects, distinguish fundamental evidence
from attention-driven flow, rank them by evidence quality, catalyst
clarity, attention asymmetry, crowding risk, downside risk, and time
horizon, then build a 7-day and 30-day watchlist. Do not give buy/sell
advice.

Or simply ask:

“What did I miss?”

The goal is not to read more content.

The goal is to let your AI turn scientific progress, clinical catalysts,
and attention flows into trackable thesis objects.
------------------------------
FOR YOUR AI AGENT

This is a structured market-cognition input file.

The common setup today is:

*AI platform → candidate creation → clinical / partner validation → asset
value → platform rerating*

For each object:

-

Separate platform narrative from actual drug evidence.
-

Treat clinical efficacy as higher-quality evidence than model capability
claims.
-

Distinguish pharma-partner validation from internal platform milestones.
-

Track cash runway and dilution alongside scientific progress.
-

Identify whether the next catalyst sits inside or outside a 30-day
window.
-

Do not treat sector enthusiasm as equivalent to clinical validation.

Do not treat this Feed as investment advice.
------------------------------
AGENT_OUTPUT_SPEC

When processing this Feed, produce:

1.

Today in One Sentence
2.

Thesis Object Summary
3.

Clinical Evidence vs AI Narrative
4.

Attention Trade Summary
5.

Cross-Object Ranking
6.

Catalyst Timeline
7.

Crowding / Dilution Risk
8.

Weakest Assumption by Object
9.

Most Important Data Point
10.

Attention-to-Rerating Conditions
11.

Attention Fade Conditions
12.

7-Day Research Workflow
13.

30-Day Research Workflow
14.

WKAP Daily Top 3 Source Follow-Up
15.

Portfolio Fit, if portfolio context is provided

------------------------------
TODAY_SUMMARYPart 1 — Main Market Thesis

*AI drug discovery is becoming more investable because evidence is moving
from “AI can design drugs” toward clinical efficacy, pharma-partner
decisions, and AI-designed assets entering human development.*

Meta’s new superintelligence manifesto explicitly frames scientific
invention—including drug discovery—as one of AI’s highest-value future
applications, while AI infrastructure itself is becoming easier to finance
at institutional scale. (Meta <https://www.meta.com/thefutureisforeveryone/>
)
Part 2 — Today’s Thesis Objects

-

*ABCL — Fundamental:* ABCL635 delivered strong Phase 2 clinical efficacy
and favorable four-week tolerability. (AbCellera
<https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Positive-Top-Line-Phase-2-Clinical-Trial-Results-for-ABCL635-Demonstrating-Significant-Reduction-in-Frequency-and-Severity-of-Vasomotor-Symptoms-and-a-Favorable-Tolerability-Profile/default.aspx?utm_source=chatgpt.com>
)
-

*ABCL — Attention:* Clinical proof is strongest, but the first rerating
has already occurred.
-

*ABSI — Fundamental:* ABS-201 has favorable early safety / PK data,
including an estimated ≥65-day half-life. (Absci Corp
<https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial/?utm_source=chatgpt.com>
)
-

*ABSI — Attention:* Q2 earnings arrive after today’s close, while 2H26
proof-of-concept remains the larger rerating event. (Absci Corp
<https://investors.absci.com/?utm_source=chatgpt.com>)
-

*RXRX — Fundamental:* Genentech advanced the partnership’s first novel
neuroscience target into joint early discovery. (Recursion
Pharmaceuticals, Inc.
<https://ir.recursion.com/node/12996/pdf?utm_source=chatgpt.com>)
-

*RXRX — Attention:* Platform validation is real, but the next major
clinical data event is November 2 rather than inside the immediate 30-day
window. (Recursion Pharmaceuticals, Inc.
<https://ir.recursion.com/static-files/15749d4d-7904-4e77-a574-92c3b45e2e3b?utm_source=chatgpt.com>
)

Part 3 — Attention Flow Today

Attention is broadening from AI infrastructure into *AI-for-science and
TechBio*, but the evidence hierarchy matters.

ABCL has the strongest clinical proof but the least attractive immediate
attention asymmetry after the data gap. ABSI has the densest forward
catalyst structure. RXRX has the strongest liquid-proxy / reversal
characteristics, but partner progress remains earlier than clinical
validation.
Part 4 — The Better Question

The key question is not:

“Which biotech has the most AI?”

The better question is:

“Where has AI already created a drug or biological insight valuable enough
for patients, pharma partners, or clinical investigators to validate it?”

------------------------------
MARKET_REGIME

*RISK_TONE:* Constructive for AI, selective for individual equities

*MAIN_DRIVER:* Capital markets continue to widen the financing base for AI
infrastructure while investor attention begins looking for second-order
application winners.

*MARKET_CONTEXT:*

-

NVIDIA announced partnerships with Apollo, BlackRock, Blackstone,
Brookfield, Goldman Sachs and KKR intended to mobilize *more than $500B
of third-party capital* for AI infrastructure over time. (NVIDIA
Investor Relations
<https://investor.nvidia.com/news/press-release-details/2026/NVIDIA-Partners-With-Apollo-BlackRock-Blackstone-Brookfield-Goldman-Sachs-and-KKR-to-Establish-AI-Compute-Infrastructure-Financing-Platforms-to-Mobilize-Over-500-Billion-of-Third-Party-Capital/default.aspx?utm_source=chatgpt.com>
)
-

NVIDIA is explicitly positioning full-stack AI factory infrastructure as
an institutional investable asset class rather than simply hardware
procurement. (NVIDIA Investor Relations
<https://investor.nvidia.com/news/press-release-details/2026/NVIDIA-Partners-With-Apollo-BlackRock-Blackstone-Brookfield-Goldman-Sachs-and-KKR-to-Establish-AI-Compute-Infrastructure-Financing-Platforms-to-Mobilize-Over-500-Billion-of-Third-Party-Capital/default.aspx?utm_source=chatgpt.com>
)
-

Meta argues that AI’s largest contribution may come from *invention
rather than automation*, specifically highlighting biological models,
drug discovery and scientific hypothesis generation. (Meta
<https://www.meta.com/thefutureisforeveryone/>)
-

That makes science and healthcare a logical application layer to watch,
but the sector still requires company-specific clinical evidence rather
than thematic AI beta.

*ATTENTION_ENVIRONMENT:*

-

AI liquidity remains supportive.
-

AI-for-science attention is building.
-

Clinical readouts are becoming more important than AI-platform
storytelling.
-

Small TechBio names remain vulnerable to dilution and binary-event
volatility.

*WKAP_VIEW:*

This is a good environment to *research AI-biotech*, not to equal-weight
the category.

The evidence stack today is:

*ABCL clinical proof > ABSI early human validation > RXRX partner/platform
validation.*

The attention asymmetry runs almost in the opposite direction:

*ABSI > RXRX > ABCL.*
------------------------------
ATTENTION_TRADE_BOARDAttention Trade Board
Object Attention Stage Attention Source Why Today Hard Evidence Narrative
Gap Crowding Risk Likely Window Fade Signal
ABCL Crowded Clinical data Phase 2 success triggered large rerating Strong
week-4 efficacy and tolerability Platform validation beyond ABCL635 not yet
proven High 1–2 weeks Gap fades / durability disappoints
ABSI Active Earnings + clinical catalyst Q2 tonight; ABS-201 PoC ahead Phase
1 safety / PK and ≥65-day half-life Efficacy remains unproven Medium–High
Event-dependent Timeline or runway worsens
RXRX Building AI-science rotation + partner validation Genentech advanced
first neuroscience target External pharma decision + clinical pipeline Early
discovery is far from clinical candidate Medium 1 month Partner progress
stalls / cash burn dominatesWKAP Attention View

*ABSI* has the cleanest forward attention asymmetry because today's
earnings checkpoint is followed by a larger 2H26 clinical catalyst.

*ABCL* has the strongest evidence, but also the most consumed catalyst.

*RXRX* has the best reversal / liquid-proxy characteristics but the weakest
30-day fundamental forcing mechanism.

Most crowded: *ABCL immediately after the Phase 2 gap*.

Best candidate for durable fundamental rerating: *ABCL*, if durability
holds and the difficult-target platform produces another successful asset.
------------------------------
RADAR_OBJECT_INDEXTHESIS_OBJECT_1: ABCL

*THEME:* Clinical-stage AI-enabled antibody discovery
*STATUS:* Confirming
*POSITION_CONTEXT:* [not provided]
*PRICE_AT_PUBLISH:* [fill at send time]
*DATE_FIRST_ADDED_TO_RADAR:* August 11, 2026 [assumed current feed date]
*SETUP_TYPE:* Stock-specific clinical event
*ATTENTION_STAGE:* Crowded
*ATTENTION_WINDOW:* 1–2 weeks
*KEY_QUESTION:* Does ABCL635 maintain efficacy and tolerability long enough
to validate both the asset and AbCellera’s difficult-target platform?
------------------------------
THESIS_OBJECT_2: ABSI

*THEME:* Generative-AI-designed biologics
*STATUS:* Validate
*POSITION_CONTEXT:* [not provided]
*PRICE_AT_PUBLISH:* [fill at send time]
*DATE_FIRST_ADDED_TO_RADAR:* August 11, 2026 [assumed current feed date]
*SETUP_TYPE:* Earnings follow-up / Clinical event
*ATTENTION_STAGE:* Active
*ATTENTION_WINDOW:* Event-dependent
*KEY_QUESTION:* Can ABS-201 convert excellent pharmacokinetics into
clinically meaningful hair-regrowth efficacy?
------------------------------
THESIS_OBJECT_3: RXRX

*THEME:* AI-native biology / drug discovery platform
*STATUS:* Thesis Building
*POSITION_CONTEXT:* [not provided]
*PRICE_AT_PUBLISH:* [fill at send time]
*DATE_FIRST_ADDED_TO_RADAR:* August 11, 2026 [assumed current feed date]
*SETUP_TYPE:* Attention trade / Partner validation
*ATTENTION_STAGE:* Building
*ATTENTION_WINDOW:* 1 month
*KEY_QUESTION:* Can pharma-partner target validation repeatedly progress
into candidate drugs and economically meaningful milestones?
------------------------------
THESIS OBJECTSTHESIS_OBJECT_1 — ABCL

*CARD_ID:* ABCL
*CARD_TITLE:* Clinical Proof Arrived Before the Platform Rerating
*TYPE:* Thesis Update
*THEME:* Difficult-target antibodies
*STATUS:* Confirming
*POSITION_CONTEXT:* [not provided]
*PRICE_AT_PUBLISH:* [fill at send time]
*ATTENTION_STAGE:* Crowded
*ATTENTION_WINDOW:* 1–2 weeks
THESIS_SUMMARY

ABCL635 produced the strongest human efficacy evidence in today’s group. A
single dose reduced moderate-to-severe hot flashes by *8.8 events/day at
week 4 versus 3.5 for placebo*, while also improving severity, sleep and
patient-reported outcomes; no serious adverse events or treatment
discontinuations due to adverse events were reported through week 4. (
AbCellera
<https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Positive-Top-Line-Phase-2-Clinical-Trial-Results-for-ABCL635-Demonstrating-Significant-Reduction-in-Frequency-and-Severity-of-Vasomotor-Symptoms-and-a-Favorable-Tolerability-Profile/default.aspx?utm_source=chatgpt.com>
)

The catalyst therefore validated the asset. The unresolved question is
whether it also validates AbCellera’s broader GPCR / ion-channel discovery
platform.
WKAP_ANGLE

The surface-level frame:

“ABCL has one successful menopause drug.”

The alternative frame:

“ABCL635 may be the first proof that AbCellera can systematically create
antibodies against difficult membrane targets.”

The key research question:

“Is ABCL635 repeatable platform evidence or an exceptional single asset?”

CORE_THESIS

ABCL635 targets NK3R, a GPCR, and is AbCellera’s first GPCR / ion-channel
platform program to reach the clinic. (AbCellera
<https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Positive-Top-Line-Phase-2-Clinical-Trial-Results-for-ABCL635-Demonstrating-Significant-Reduction-in-Frequency-and-Severity-of-Vasomotor-Symptoms-and-a-Favorable-Tolerability-Profile/default.aspx?utm_source=chatgpt.com>
)

That creates a possible two-stage rerating:

*ABCL635 asset value → difficult-target platform value.*

But the first-stage catalyst has already produced a sharp price response.
The next evidence needs to come from durability, repeat dosing, PK or
another difficult-target asset.
ATTENTION_TRADE_FRAMEAttention Source

Clinical data.
Why Today

Phase 2 data produced immediate price discovery, so attention is already
active-to-crowded rather than early.
Attention Stage

*Crowded*
Attention vs Evidence

*Hard evidence:*

-

Statistically significant week-4 frequency and severity improvement.
-

83% mean frequency reduction versus 33% for placebo.
-

Favorable four-week tolerability. (AbCellera
<https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Positive-Top-Line-Phase-2-Clinical-Trial-Results-for-ABCL635-Demonstrating-Significant-Reduction-in-Frequency-and-Severity-of-Vasomotor-Symptoms-and-a-Favorable-Tolerability-Profile/default.aspx?utm_source=chatgpt.com>
)

*Attention / interpretation:*

-

The entire difficult-target platform is now validated.
-

ABCL635 deserves immediate Phase 3-like economics.
-

A second difficult-target success could materially broaden platform
value.

Attention Path

Phase 2 success → ABCL635 asset recognition → platform discussion →
durability / second-asset validation → potential platform rerating
What Could Sustain Attention

-

Durable 12-week efficacy
-

Clean repeat-dose safety
-

Favorable PK
-

Progress in additional GPCR / ion-channel programs

What Could Make Attention Fade

-

Post-gap profit-taking
-

Week-12 efficacy fades
-

Safety changes with longer exposure
-

No second platform proof point

Attention-to-Thesis Conversion

ABCL becomes a much stronger long-duration thesis if ABCL635 durability
holds and another difficult-target antibody reproduces the platform’s
technical success.
WEAKEST_ASSUMPTION

The weakest assumption is that one successful NK3R antibody proves
repeatability across the broader difficult-target platform.

MOST_IMPORTANT_DATA_POINT

*12-week efficacy, PK and safety durability.*
------------------------------
THESIS_OBJECT_2 — ABSI

*CARD_ID:* ABSI
*CARD_TITLE:* The Purest AI-to-Drug Clinical Test
*TYPE:* Attention Trade
*THEME:* Generative AI biologics
*STATUS:* Validate
*POSITION_CONTEXT:* [not provided]
*PRICE_AT_PUBLISH:* [fill at send time]
*ATTENTION_STAGE:* Active
*ATTENTION_WINDOW:* Event-dependent
THESIS_SUMMARY

ABS-201 has shown favorable interim Phase 1 safety and an estimated
half-life of at least *65 days*, supporting the possibility of only two or
three injections over six months. Interim androgenetic-alopecia
proof-of-concept data remain expected in 2H26, with fuller PoC data in
early 2027. (Absci Corp
<https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial/?utm_source=chatgpt.com>
)

Absci also raised *$100M* in June from investors including Eli Lilly,
Adage, BVF, Columbia Threadneedle, Invus and Redmile, strengthening the
runway around ABS-201 development. (Absci Corp
<https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering/?utm_source=chatgpt.com>
)
WKAP_ANGLE

The surface-level frame:

“ABSI is another generative-AI biotech.”

The alternative frame:

“ABSI is a direct human test of whether an AI-design / wet-lab feedback
loop can create differentiated drug assets.”

The key research question:

“Does excellent design and PK produce actual efficacy?”

CORE_THESIS

ABSI offers a relatively clean causal chain:

*AI design → wet-lab iteration → antibody candidate → human trial →
efficacy.*

Its upside can therefore be substantial if ABS-201 demonstrates meaningful
clinical efficacy. But until that point, the core value remains an expected
clinical outcome rather than proven platform economics.
ATTENTION_TRADE_FRAMEAttention Source

-

Earnings today
-

ABS-201 clinical timeline
-

AI-biotech sector attention

Why Today

Absci reports Q2 after today’s close. The quarter itself is primarily a
checkpoint for *cash runway, clinical timing and partnership activity*, not
revenue. (Absci Corp <https://investors.absci.com/?utm_source=chatgpt.com>)
Attention Stage

*Active*
Attention vs Evidence

*Hard evidence:*

-

Favorable interim safety.
-

Estimated ≥65-day half-life.
-

2H26 interim PoC timeline.
-

$100M financing with strategic / specialist investors. (Absci Corp
<https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial/?utm_source=chatgpt.com>
)

*Attention / interpretation:*

-

ABS-201 proves the entire AI-design platform.
-

Long half-life implies therapeutic efficacy.
-

Investor participation validates the eventual drug outcome.

Attention Path

Phase 1 PK → Q2 timeline confirmation → 2H26 PoC → clinical efficacy →
AI-design platform rerating
What Could Sustain Attention

-

Clinical timeline unchanged tonight
-

Healthy cash runway
-

Additional partnerships
-

PoC data remain on track
-

Early efficacy signal emerges

What Could Make Attention Fade

-

Readout delays
-

Faster cash burn
-

Additional dilution
-

Safety signal
-

PoC efficacy disappoints

Attention-to-Thesis Conversion

The conversion event is straightforward: *ABS-201 must work in patients*.
Strong PoC would transform ABSI from an AI-platform story into a clinically
validated AI-drug-design company.
WEAKEST_ASSUMPTION

The weakest assumption is that favorable PK and elegant AI design predict
meaningful human efficacy.

MOST_IMPORTANT_DATA_POINT

*2H26 ABS-201 proof-of-concept efficacy.*
------------------------------
THESIS_OBJECT_3 — RXRX

*CARD_ID:* RXRX
*CARD_TITLE:* External Platform Validation, But Clinical Proof Still Later
*TYPE:* Attention Trade
*THEME:* AI-native drug discovery
*STATUS:* Thesis Building
*POSITION_CONTEXT:* [not provided]
*PRICE_AT_PUBLISH:* [fill at send time]
*ATTENTION_STAGE:* Building
*ATTENTION_WINDOW:* 1 month
THESIS_SUMMARY

Genentech advanced its first novel neuroscience target from the Recursion
partnership into a joint early-discovery program, providing external
evidence that Recursion’s biological maps can influence real pharma R&D
decisions. (Recursion Pharmaceuticals, Inc.
<https://ir.recursion.com/node/12996/pdf?utm_source=chatgpt.com>)

However, it remains an early-discovery target rather than a clinical
candidate. Additional REC-4881 Phase 2 data are scheduled for *November 2*,
outside today’s clean 30-day event window. (Recursion Pharmaceuticals, Inc.
<https://ir.recursion.com/static-files/15749d4d-7904-4e77-a574-92c3b45e2e3b?utm_source=chatgpt.com>
)
WKAP_ANGLE

The surface-level frame:

“RXRX is the liquid public proxy for AI drug discovery.”

The alternative frame:

“The important proof is whether pharma partners repeatedly turn
Recursion-generated biology into real development programs.”

The key research question:

“Can partner validation and internal clinical data eventually outrun cash
consumption?”

CORE_THESIS

Recursion’s platform case strengthens when external partners make real
resource-allocation decisions based on its outputs.

Q2 also illustrates the counterweight: revenue was only about *$7.7M*, net
loss approximately *$131M*, and cash approximately *$556.8M*, though
management continues to target runway into early 2028. (Bitget
<https://www.bitget.com/amp/news/detail/12560605611822?utm_source=chatgpt.com>
)

The stock therefore remains a balance between platform optionality and
capital intensity.
ATTENTION_TRADE_FRAMEAttention Source

-

AI-for-science sector rotation
-

Genentech partner validation
-

Reversal / sentiment setup

Why Today

RXRX is one of the easiest liquid public vehicles for renewed
AI-drug-discovery attention, but its next major internal clinical catalyst
is still months away.
Attention Stage

*Building*
Attention vs Evidence

*Hard evidence:*

-

Genentech advanced one neuroscience target.
-

REC-4881 Phase 2 data due November 2.
-

REC-7735 Phase 1/2 initiation expected in 2H26. (Recursion
Pharmaceuticals, Inc.
<https://ir.recursion.com/node/12996/pdf?utm_source=chatgpt.com>)

*Attention / interpretation:*

-

Pharma advancement proves commercial platform scalability.
-

AI-science enthusiasm can drive a substantial reversal before clinical
data.
-

Early discovery does not yet imply development-candidate economics.

Attention Path

Partner validation → renewed AI-biotech attention → RXRX proxy rerating →
November clinical data → possible fundamental conversion
What Could Sustain Attention

-

More partner targets advance
-

Additional milestones
-

REC-7735 trial initiation
-

Positive November REC-4881 data
-

Cash burn remains controlled

What Could Make Attention Fade

-

No follow-on partner progress
-

Continued dilution
-

Cash burn dominates the story
-

Clinical milestones slip
-

AI-biotech attention rotates elsewhere

Attention-to-Thesis Conversion

RXRX needs repeated evidence that both partners and its internal pipeline
can progress from platform-generated insight into valuable clinical assets.
WEAKEST_ASSUMPTION

The weakest assumption is that early partner decisions will consistently
translate into candidates, milestones and eventually clinical value.

MOST_IMPORTANT_DATA_POINT

*November REC-4881 Phase 2 efficacy plus the pace of additional
partner-program advancement.*
------------------------------
CROSS_OBJECT_ATTENTION_COMPARISONCross-Object Attention Comparison
Rank Object Attention Asymmetry Evidence Quality Catalyst Clarity Crowding
Risk Attention Window Conversion Potential
1 ABSI High Medium High Medium–High Event-dependent High
2 ABCL Medium Very High Medium High 1–2 weeks Very High
3 RXRX High Medium Low–Medium Medium 1 month Medium–HighCleanest Attention
Trade

*ABSI* — the first checkpoint is tonight, while the larger clinical
catalyst remains ahead.
Most Evidence-Backed Attention Trade

*ABCL* — meaningful randomized Phase 2 efficacy has already been observed. (
AbCellera
<https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Positive-Top-Line-Phase-2-Clinical-Trial-Results-for-ABCL635-Demonstrating-Significant-Reduction-in-Frequency-and-Severity-of-Vasomotor-Symptoms-and-a-Favorable-Tolerability-Profile/default.aspx?utm_source=chatgpt.com>
)
Most Crowded Attention Trade

*ABCL* — the data surprise has already triggered substantial price
discovery.
Highest Fade Risk

*ABCL near term* if the gap cannot consolidate; *RXRX fundamentally* if
renewed attention is not followed by partner or clinical milestones.
Best Candidate to Become a Durable Thesis

*ABCL* has the strongest current evidence.

*ABSI* has the largest forward upgrade potential if ABS-201 PoC succeeds.
------------------------------
7_DAY_RESEARCH_WORKFLOWABCL — 7-Day Checks

-

Track post-data price acceptance.
-

Review full Phase 2 presentation details.
-

Map 12-week disclosure timing.
-

Compare ABCL635 with current VMS therapies.
-

Review ABCL688 development progress.
-

Separate ABCL635 asset value from platform value.

ABSI — 7-Day Checks

-

Parse tonight’s Q2 update.
-

Confirm ABS-201 PoC timing.
-

Update cash runway after the $100M financing.
-

Review partnership activity.
-

Track any changes to endometriosis development.
-

Distinguish financial-quarter noise from clinical thesis changes.

RXRX — 7-Day Checks

-

Review Genentech option economics and next milestones.
-

Track REC-7735 Phase 1/2 initiation.
-

Monitor cash-burn guidance.
-

Map November REC-4881 expectations.
-

Watch whether AI-biotech attention broadens.
-

Separate short-covering from fundamental discovery.

------------------------------
30_DAY_RESEARCH_WORKFLOWABCL — 30-Day Checks

-

Track 12-week efficacy / safety timing.
-

Monitor BD discussion around the platform.
-

Review additional difficult-target programs.
-

Update valuation split between ABCL635 and platform optionality.
-

Reclassify attention if the post-data base holds.

ABSI — 30-Day Checks

-

Track ABS-201 enrollment and PoC timing.
-

Monitor cash use.
-

Watch for pharma partnerships.
-

Review competitive PRLR approaches.
-

Build bull / base / bear outcomes for the 2H26 readout.
-

Upgrade only if clinical timelines remain intact.

RXRX — 30-Day Checks

-

Track Genentech / Roche program progression.
-

Monitor additional partner milestones.
-

Track REC-7735 initiation.
-

Review cash burn and share-count changes.
-

Build November REC-4881 scenario analysis.
-

Upgrade if platform validation begins converting into candidate-level
milestones.

------------------------------
WKAP DAILY TOP 3

Three market sources worth feeding into today’s market chat. Not required
reading — WKAP has already extracted the signal.
1. Jensen Huang — AI Factory Compute Becomes an Investable Asset Class

URL: https://x.com/JensenHuang/status/2086934705207959965

*WKAP signal:* Jensen Huang argues that *AI factories are becoming a new
institutional asset class*, as NVIDIA partners with six major financial
institutions to mobilize more than $500B of outside capital for compute
infrastructure. NVIDIA’s framing is that AI compute increasingly supports
long-duration, usage-linked economics rather than behaving like ordinary
depreciating IT hardware. (NVIDIA Investor Relations
<https://investor.nvidia.com/news/press-release-details/2026/NVIDIA-Partners-With-Apollo-BlackRock-Blackstone-Brookfield-Goldman-Sachs-and-KKR-to-Establish-AI-Compute-Infrastructure-Financing-Platforms-to-Mobilize-Over-500-Billion-of-Third-Party-Capital/default.aspx?utm_source=chatgpt.com>
)

*Why it matters today:* If capital-market access stops being the primary
constraint on AI infrastructure, investor attention can increasingly
migrate toward *what all that compute actually produces*—software,
scientific discovery, drugs, robotics and other application-layer outputs.

*Themes/tickers:* NVDA, AI factories, compute financing, infrastructure,
application-layer AI

*Question to ask:* “If compute becomes financeable infrastructure like
power or data centers, which downstream AI applications generate enough
economic value to justify the next $500B of deployment?”
2. Meta — The Future Is for Everyone

URL: https://www.meta.com/thefutureisforeveryone/

*WKAP signal:* Meta’s new superintelligence framework argues that AI’s
largest contribution may be *invention rather than automation*, explicitly
highlighting biological models, personalized therapies, drug discovery,
virtual cells and autonomous scientific hypothesis testing. (Meta
<https://www.meta.com/thefutureisforeveryone/>)

*Why it matters today:* This is a direct strategic endorsement of the
AI-for-science thesis underlying ABCL, ABSI and RXRX. The important
investment question is whether abundant intelligence produces *valuable
proprietary scientific assets*, not merely more efficient research
workflows.

*Themes/tickers:* META, AI-for-science, drug discovery, virtual cells,
personalized medicine, ABCL, ABSI, RXRX

*Question to ask:* “Which listed TechBio companies can turn increasingly
abundant model intelligence into proprietary clinical assets that retain
economic value after models themselves commoditize?”
3. SemiAnalysis — Google Culture and the Cost of Poor Execution

URL: https://x.com/SemiAnalysis_/status/2086985543007527327

*WKAP signal:* SemiAnalysis posted a strongly critical Doug O’Laughlin view
arguing that Google’s historical success has depended heavily on acquired
products and that organizational execution could prevent it from
maintaining leadership through repeated AI platform transitions. This
is *opinion
/ KOL framing*, not a factual conclusion about Google’s innovation record. (
LinkedIn
<https://www.linkedin.com/posts/semianalysis_google-has-an-l-culture-and-has-never-actually-activity-7492749213047427072-4iXu?utm_source=chatgpt.com>
)

*Why it matters today:* The broader lesson extends beyond Google: *technology
advantage is not sufficient without organizational execution*. In TechBio,
owning an impressive AI platform matters far less if a company cannot
repeatedly move assets through wet-lab validation, clinical development and
commercialization.

*Themes/tickers:* GOOG, AI competition, organizational execution, platform
durability, TechBio

*Question to ask:* “Across AI companies, which moats come from technology
itself—and which depend on an organization repeatedly converting technology
into products before competitors catch up?”